Fundamental Analysis of CYBIN INC(NYSEARCA:CYBN) stock

Fundamental Rating

Overall CYBN gets a fundamental rating of 3 out of 10. We evaluated CYBN against 194 industry peers in the Pharmaceuticals industry. While CYBN has a great health rating, there are worries on its profitability. CYBN is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

CYBN had negative earnings in the past year.

In the past year CYBN has reported a negative cash flow from operations.

CYBN had negative earnings in each of the past 5 years.

CYBN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

CYBN has a Return On Assets of -27.54%. This is comparable to the rest of the industry: CYBN outperforms 57.81% of its industry peers.

Looking at the Return On Equity, with a value of -28.01%, CYBN is in the better half of the industry, outperforming 67.71% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-27.54%
ROE	-28.01%
ROIC	N/A

ROA(3y)-54.26%

ROA(5y)N/A

ROE(3y)-60.72%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CYBN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, CYBN has more shares outstanding

CYBN has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 37.21 indicates that CYBN is not in any danger for bankruptcy at the moment.

With an excellent Altman-Z score value of 37.21, CYBN belongs to the best of the industry, outperforming 93.75% of the companies in the same industry.

There is no outstanding debt for CYBN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	37.21

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

CYBN has a Current Ratio of 41.70. This indicates that CYBN is financially healthy and has no problem in meeting its short term obligations.

CYBN's Current ratio of 41.70 is amongst the best of the industry. CYBN outperforms 97.40% of its industry peers.

A Quick Ratio of 41.70 indicates that CYBN has no problem at all paying its short term obligations.

CYBN has a better Quick ratio (41.70) than 97.40% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	41.7
Quick Ratio	41.7

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CYBN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -538.46%.

The Revenue for CYBN has decreased by -100.00% in the past year. This is quite bad

EPS 1Y (TTM)-538.46%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-985.71%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 84.05% on average over the next years. This is a very strong growth

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-2064.07%

EPS Next 2Y-405.14%

EPS Next 3Y-111.08%

EPS Next 5Y84.05%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CYBN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYBN. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as CYBN's earnings are expected to decrease with -111.08% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-405.14%

EPS Next 3Y-111.08%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CYBN!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CYBIN INC

NYSEARCA:CYBN (11/15/2024, 8:04:01 PM)

After market: 12.1399 +0.54 (+4.65%)

11.6

+0.6 (+5.45%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap231.88M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-27.54%
ROE	-28.01%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	41.7
Quick Ratio	41.7
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-538.46%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-2064.07%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CYBIN INC (CYBN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens